Oral squamous cell carcinoma (OSCC) is the most common form of head and neck cancer, and the number of new cases is predicted to rise by 30% in the next decade. Despite decades of cancer research, treating OSCC remains a challenge. The five-year survival rate is approximately 50%, and standard treatments such as ablative surgery and radiation often leave patients with permanent disfigurement or profound, lifelong impairment of essential oral functions such as speaking and swallowing.